[go: up one dir, main page]

PE20170125A1 - Receptor antigenico quimerico (car) que comprende un dominio de union de antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t - Google Patents

Receptor antigenico quimerico (car) que comprende un dominio de union de antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t

Info

Publication number
PE20170125A1
PE20170125A1 PE2016001548A PE2016001548A PE20170125A1 PE 20170125 A1 PE20170125 A1 PE 20170125A1 PE 2016001548 A PE2016001548 A PE 2016001548A PE 2016001548 A PE2016001548 A PE 2016001548A PE 20170125 A1 PE20170125 A1 PE 20170125A1
Authority
PE
Peru
Prior art keywords
car
trbc1
seq
trbc2
constant region
Prior art date
Application number
PE2016001548A
Other languages
English (en)
Inventor
Martin Pule
Paul Maciocia
Original Assignee
Ucl Business Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52649058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20170125(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB201403905A external-priority patent/GB201403905D0/en
Priority claimed from GB201416908A external-priority patent/GB201416908D0/en
Application filed by Ucl Business Plc filed Critical Ucl Business Plc
Publication of PE20170125A1 publication Critical patent/PE20170125A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se refiere a un receptor quimerico (CAR) que comprende un dominio de union a antigenos, el cual se une selectivamente a la region constante del TCR beta 1 (TRBC1) o TRBC2 de celulas T; el CAR que se une a TRBC1 en donde donde el dominio de union a antigenos tiene una cadena pesada variable (VH) que comprende: CDR1 de SEQ ID NO; 7, CDR2 de SEQ ID NO: 8, CDR3 de SEQ ID NO: 9 y una cadena ligera variable (VL) que comprende: CDR1 de SEQ ID NO: 10, CDR2 de SEQ ID NO: 11 y CDR3 de SEQ ID NO: 12. Tambien se refiere a un metodo. Dicha invencion es util en el tratamiento de linfoma o leucemia de celulas T
PE2016001548A 2014-03-05 2015-03-05 Receptor antigenico quimerico (car) que comprende un dominio de union de antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t PE20170125A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201403905A GB201403905D0 (en) 2014-03-05 2014-03-05 Method
GB201416908A GB201416908D0 (en) 2014-09-25 2014-09-25 Method

Publications (1)

Publication Number Publication Date
PE20170125A1 true PE20170125A1 (es) 2017-03-16

Family

ID=52649058

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2021000759A PE20211887A1 (es) 2014-03-05 2015-03-05 Receptor antigenico quimerico (car) que comprende un dominio de union a antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t
PE2016001548A PE20170125A1 (es) 2014-03-05 2015-03-05 Receptor antigenico quimerico (car) que comprende un dominio de union de antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2021000759A PE20211887A1 (es) 2014-03-05 2015-03-05 Receptor antigenico quimerico (car) que comprende un dominio de union a antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t

Country Status (24)

Country Link
US (2) US20170066827A1 (es)
EP (3) EP3125934B1 (es)
JP (5) JP6767872B2 (es)
KR (3) KR102235201B1 (es)
CN (4) CN112094353A (es)
AU (3) AU2015225944B2 (es)
BR (1) BR112016020304B1 (es)
CA (1) CA2940564C (es)
CL (4) CL2016002195A1 (es)
CU (1) CU24475B1 (es)
DK (2) DK3125934T3 (es)
ES (2) ES2758173T3 (es)
FI (1) FI3241561T3 (es)
HU (2) HUE047641T2 (es)
IL (3) IL278879B1 (es)
MX (3) MX2016010856A (es)
MY (1) MY173567A (es)
PE (2) PE20211887A1 (es)
PH (3) PH12020550202B1 (es)
PL (2) PL3125934T3 (es)
PT (2) PT3125934T (es)
RU (2) RU2744046C2 (es)
SG (3) SG10201906461SA (es)
WO (1) WO2015132598A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11385233B2 (en) 2015-03-05 2022-07-12 Autolus Limited Methods of depleting malignant T-cells
US11982672B2 (en) 2014-03-05 2024-05-14 Autolus Limited Methods
GB201403972D0 (en) 2014-03-06 2014-04-23 Ucl Business Plc Chimeric antigen receptor
WO2016051205A1 (en) * 2014-10-03 2016-04-07 Isis Innovation Limited Analysis of t-cell monotypia
CA2937157A1 (en) * 2016-07-25 2018-01-25 Ucl Business Plc Protein-based t-cell receptor knockdown
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
EP3579848B1 (en) 2017-02-08 2024-10-30 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
AU2018220736B2 (en) 2017-02-20 2024-10-24 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
MA49039A (fr) 2017-04-04 2020-02-12 Hoffmann La Roche Nouvelles molécules bispécifiques de liaison à l'antigène capables de se lier spécifiquement à cd40 et à fap
GB201709203D0 (en) * 2017-06-09 2017-07-26 Autolus Ltd Antigen-binding domain
WO2019025800A1 (en) * 2017-08-02 2019-02-07 Autolus Limited CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
AU2018322178A1 (en) * 2017-08-23 2020-02-20 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
JP7372920B2 (ja) * 2017-12-29 2023-11-01 セレクティス Ｃａｒ ｔ細胞の作製を改良するための方法
WO2019129850A1 (en) * 2017-12-29 2019-07-04 Cellectis Off-the-shelf engineered cells for therapy
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
GB201800298D0 (en) * 2018-01-09 2018-02-21 Autolus Ltd Method
EP3765054A4 (en) * 2018-01-19 2022-01-12 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR TARGETING GAMMA DELTA T LYMPHOCYTES USING CHIMERIC ANTIGEN RECEPTORS
PE20210375A1 (es) 2018-02-08 2021-03-02 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales
WO2019157366A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
JP7554742B2 (ja) 2018-07-03 2024-09-20 マレンゴ・セラピューティクス，インコーポレーテッド 抗ｔｃｒ抗体分子およびその使用
WO2020010229A1 (en) * 2018-07-06 2020-01-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Car t cell therapy to target t cell specific cancers
US20210277120A1 (en) * 2018-07-18 2021-09-09 The General Hospital Corporation Compositions and methods for treatment of t cell malignancies
GB201812650D0 (en) * 2018-08-03 2018-09-19 Autolus Ltd Molecular assessment of TRBC usage
KR20210043602A (ko) 2018-08-08 2021-04-21 드래곤플라이 쎄라퓨틱스, 인크. Bcma, nkg2d 및 cd16에 결합하는 다중특이성 결합 단백질 및 이의 사용 방법
JP7482363B2 (ja) 2018-08-08 2024-05-14 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及び腫瘍関連抗原に結合するタンパク質
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
GB201817172D0 (en) 2018-10-22 2018-12-05 Autolus Ltd Antibody
GB201817822D0 (en) * 2018-10-31 2018-12-19 Autolus Ltd Binding domain
JP2022523502A (ja) * 2019-01-29 2022-04-25 シャンハイ ジャオ トン ユニバーシティ キメラ抗原受容体およびその使用
CN114127112A (zh) * 2019-02-21 2022-03-01 马伦戈治疗公司 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
EP3927744A1 (en) * 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CN114127111B (zh) 2019-02-21 2024-09-10 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
CN110317266A (zh) * 2019-07-17 2019-10-11 东北农业大学 三种scFv抗体、其编码基因及其在制备治疗或预防O型口蹄疫病制剂中的应用
EP4121518A4 (en) * 2020-03-16 2024-06-19 Marengo Therapeutics, Inc. MODIFIED CELL COMPOSITIONS AND METHODS OF USE
GB202004263D0 (en) * 2020-03-24 2020-05-06 Autolus Ltd Antibody conjugate
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
GB202101491D0 (en) 2021-02-03 2021-03-17 Autolus Ltd Molecule
EP4132962A1 (en) 2020-04-09 2023-02-15 Autolus Limited Molecule
CA3180321A1 (en) * 2020-04-24 2021-10-28 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CN115836088A (zh) 2020-05-06 2023-03-21 蜻蜓疗法股份有限公司 结合nkg2d、cd16和clec12a的蛋白质
CN111537735A (zh) * 2020-05-15 2020-08-14 江西赛基生物技术有限公司 抗体检测试剂盒以及在免疫分析方面的应用
CN111549044B (zh) * 2020-07-13 2020-10-23 北京市肿瘤防治研究所 靶向trbc1 car-t细胞的制备方法与应用
US12173318B2 (en) 2020-08-18 2024-12-24 Medigene Immunotherapies Gmbh Enrichment of T cells using an anti-Cß antibody
EP4204458A4 (en) * 2020-08-26 2024-10-09 Marengo Therapeutics, Inc. METHODS FOR DETECTION OF TRBC1 OR TRBC2
EP4294841A1 (en) * 2021-02-17 2023-12-27 The Johns Hopkins University Methods and materials for treating clonal t cell expansions
US20220267415A1 (en) * 2021-02-17 2022-08-25 The Board Of Regents Of The University Of Texas System Multimeric sars-cov-2 binding molecules and uses thereof
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
GB202112923D0 (en) * 2021-09-10 2021-10-27 Ucl Business Ltd Binding domain
EP4606385A1 (en) 2022-10-18 2025-08-27 Meiji Seika Pharma Co., Ltd. Therapeutic agent for t cell tumor
WO2024236163A1 (en) 2023-05-17 2024-11-21 Morphosys Ag T cell receptor beta constant region 2 (trbc2) antibodies
WO2024256824A1 (en) 2023-06-14 2024-12-19 Autolus Limited Chimeric antigen receptors directed against trbc1 and trbc2
WO2025007013A2 (en) * 2023-06-28 2025-01-02 The Johns Hopkins University Trbc targeting antibody-drug conjugates
GB202310981D0 (en) 2023-07-18 2023-08-30 Autolus Ltd Method
WO2025051339A1 (en) * 2023-09-05 2025-03-13 Tiber Biotech Srl SINGLE-CHAIN VARIABLE FRAGMENT AND MOLECULES DERIVING THEREFROM THAT BIND FRAGMENT TRVB5-1 OF THE β CHAIN OF HUMAN T-CELL RECEPTOR
WO2025096673A1 (en) * 2023-10-30 2025-05-08 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising cells targeting cancer and methods of using the same
WO2025202622A1 (en) * 2024-03-26 2025-10-02 Oxford University Innovation Limited Antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06502529A (ja) * 1990-08-09 1994-03-24 ナショナル　ジューイッシュ　センター　フォア　イミュノロジィ　アンド　レスパラトリィ　メディスン 組換えｄｎａベクターを使用するヒトｔ細胞受容体要素に対するモノクローナル抗体の製造方法
US6790604B1 (en) * 1998-05-12 2004-09-14 Stefan A. Cohen Methods for identifying or diagnosing carcinoma cells with metastatic potential based on the measurement of lymphoid genes or their products in carcinoma cells
AU2003233197A1 (en) * 2002-04-29 2003-11-17 Genpat77 Pharmacogenetics Ag Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis
RU2355703C2 (ru) * 2002-10-09 2009-05-20 Медиджен Лимитед Одноцепочечные рекомбинантные т-клеточные рецепторы
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances
US7741045B2 (en) * 2006-11-16 2010-06-22 General Electric Company Sequential analysis of biological samples
WO2009151628A2 (en) * 2008-06-12 2009-12-17 Gov't Of The Usa, As Represented By The Secretary, Department Of Health Human Services Monitoring tcr-b to determine hiv therapy and disease progression
CA2735193A1 (en) * 2008-08-26 2010-03-11 Macrogenics, Inc. T-cell receptor antibodies and methods of use thereof
RS55229B1 (sr) * 2009-12-29 2017-02-28 Emergent Product Dev Seattle Heterodimerni vezujući proteini i njihove upotrebe
JP6000507B2 (ja) * 2010-09-30 2016-09-28 パナソニックヘルスケアホールディングス株式会社 診療情報登録装置
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013074916A1 (en) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
KR102437522B1 (ko) * 2012-05-25 2022-08-26 셀렉티스 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
US10443100B2 (en) * 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
KR20170083534A (ko) * 2014-09-19 2017-07-18 리제너론 파마슈티칼스 인코포레이티드 키메라 항원 수용체
WO2016160721A1 (en) * 2015-03-27 2016-10-06 President And Fellows Of Harvard College Modified t cells and methods of making and using the same

Also Published As

Publication number Publication date
BR112016020304A2 (pt) 2017-10-17
HUE047641T2 (hu) 2020-05-28
PH12016501646A1 (en) 2017-02-06
MY173567A (en) 2020-02-04
PH12020550202A1 (en) 2022-03-07
AU2019204921A1 (en) 2019-08-01
JP2021184773A (ja) 2021-12-09
EP3241561A1 (en) 2017-11-08
IL278879B1 (en) 2025-08-01
CA2940564C (en) 2021-06-29
JP2024074907A (ja) 2024-05-31
CN112094353A (zh) 2020-12-18
WO2015132598A1 (en) 2015-09-11
SG10201906461SA (en) 2019-09-27
EP3241561B1 (en) 2025-04-30
JP6767931B2 (ja) 2020-10-14
EP3125934A1 (en) 2017-02-08
DK3125934T3 (da) 2020-02-03
CN118852462A (zh) 2024-10-29
AU2015225944B2 (en) 2019-07-11
PT3241561T (pt) 2025-06-24
FI3241561T3 (fi) 2025-07-07
RU2018140694A (ru) 2018-12-10
PH12020550202B1 (en) 2023-11-15
NZ761848A (en) 2021-06-25
KR20160127130A (ko) 2016-11-02
PE20211887A1 (es) 2021-09-22
JP6767872B2 (ja) 2020-10-14
JP2017143838A (ja) 2017-08-24
CN106068276B (zh) 2020-09-18
IL278878A (en) 2021-01-31
CA2940564A1 (en) 2015-09-11
US20170334998A1 (en) 2017-11-23
AU2019204925B2 (en) 2021-02-18
CL2016002195A1 (es) 2017-05-19
BR112016020304B1 (pt) 2024-02-27
KR20200027577A (ko) 2020-03-12
SG11201606583VA (en) 2016-09-29
JP7149304B2 (ja) 2022-10-06
KR20200027576A (ko) 2020-03-12
KR102235202B1 (ko) 2021-04-05
RU2744046C2 (ru) 2021-03-02
RU2021101502A (ru) 2021-06-25
AU2019204921B2 (en) 2021-02-18
EP3125934B1 (en) 2019-10-23
IL278879A (en) 2021-01-31
PH12016501646B1 (en) 2023-02-03
CN106068276A (zh) 2016-11-02
PL3125934T3 (pl) 2020-04-30
NZ723307A (en) 2021-06-25
JP2017510257A (ja) 2017-04-13
US20170066827A1 (en) 2017-03-09
CL2018003096A1 (es) 2019-01-11
MX2019013845A (es) 2020-02-24
IL247110A0 (en) 2016-09-29
NZ761844A (en) 2021-06-25
DK3241561T3 (da) 2025-06-30
ES2758173T3 (es) 2020-05-04
AU2015225944A1 (en) 2016-09-01
CL2019001568A1 (es) 2019-08-16
JP2020099356A (ja) 2020-07-02
KR102088082B1 (ko) 2020-03-11
SG10201906460PA (en) 2019-09-27
MX2019013846A (es) 2020-02-24
MX2016010856A (es) 2017-04-13
ES3033286T3 (en) 2025-08-01
AU2019204921C1 (en) 2021-05-13
RU2016138421A (ru) 2018-04-05
CL2019001567A1 (es) 2019-08-16
RU2016138421A3 (es) 2018-07-25
PT3125934T (pt) 2019-12-16
IL278878B (en) 2022-07-01
HUE071755T2 (hu) 2025-09-28
CN112094347A (zh) 2020-12-18
PL3241561T3 (pl) 2025-09-01
EP4610654A2 (en) 2025-09-03
CU24475B1 (es) 2020-03-04
PH12020550203A1 (en) 2021-08-16
KR102235201B1 (ko) 2021-04-05
AU2019204925A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
PE20170125A1 (es) Receptor antigenico quimerico (car) que comprende un dominio de union de antigenos, el cual se une selectivamente a la region constante del tcr beta 1 (trbc1) o trbc2 de celulas t
CY1125347T1 (el) Ειδικοι σε κλαουδινη-18.2 ανοσοϋποδοχεις και επιτοποι τ-κυτταρων
CY1124993T1 (el) Ετεροδιμερικα αντισωματα που δεσμευουν cd3 και cd20
CY1121539T1 (el) Ειδικοι για κλαυδiνη-6 ανοσοϋποδοχεις και επιτοποι τ-κυτταρων
MX360707B (es) Receptor antigénico quimérico.
MX385456B (es) Anticuerpos cd123 y conjugados de los mismos.
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
MX2017006233A (es) Celula.
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
MX2022002364A (es) Anticuerpos anti-pd-l1.
PE20161392A1 (es) Combinacion de lenalidomida y constructo de polipeptido, y sus usos
EA201990208A1 (ru) Химерные антигенные рецепторы, нацеленные на bcma, и способы их применения
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
MX388181B (es) Anticuerpos anti-pd-1.
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
PE20180499A1 (es) Anticuerpos de union a tau
PE20190201A1 (es) Receptores quimericos de flt3 y metodos de uso de los mismos
MY186016A (en) Anti-tigit antibodies and methods of use
MX2017009182A (es) Sistemas de receptor de antigeno quimerico impulsado por mab para clasificar/reducir celulas inmunes diseñadas.
PE20171060A1 (es) Receptores quimericos de antigeno anti-cldn y metodos de uso
EA201992756A2 (ru) Антитела против cd48 и их конъюгаты
PH12016501366A1 (en) Novel anti-baff antibodies
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
CY1121158T1 (el) Αντισωμα ικανο να αναγνωριζει ειδικα υποδοχεα τρανσφερρινης
CO2019002369A2 (es) Anticuerpo que se une específicamente a pd-1 y fragmento funcional del mismo